The short version of Semax fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-19. Anything still debated is marked as such rather than presented as settled.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Calculated for the free peptide |
| Molar mass | 813.9 g/mol | Anhydrous free base |
| Peptide class | Synthetic heptapeptide | ACTH(4-10) analogue |
| Parent fragment | ACTH(4-10) | Adrenocorticotropic hormone segment |
| Developmental origin | Institute of Molecular Genetics, Moscow | Work began in the 1980s |
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Shut-down separator (for overheating) Tear-away tab (for internal pressure relief) Vent (pressure relief in case of severe outgassing) Thermal interrupt (overcurrent/overcharging/environmental exposure) These features are required because the negative electrode produces heat during use, while the positive electrode may produce oxygen. However, these additional devices occupy space inside the cells, add points of failure, and may irreversibly disable the cell when activated. Further, these features increase costs compared to nickel metal hydride batteries, which require only a hydrogen/oxygen recombination device and a back-up pressure valve. Contaminants inside the cells can defeat these safety devices. Also, these features cannot be applied to all kinds of cells; prismatic high-current cells cannot be equipped with a vent or thermal interrupt. High-current cells must not produce excessive heat or oxygen, lest there be a failure, possibly violent. Instead, they must be equipped with internal thermal fuses which act before the anode and cathode reach their thermal limits. Replacing the lithium cobalt oxide positive electrode material with a lithium metal phosphate such as lithium iron phosphate (LFP) improves cycle counts, shelf life and safety, but lowers capacity. As of 2006, these safer lithium-ion batteries were mainly used in electric cars and other large-capacity battery applications, where safety is critical. In 2016, an LFP-based energy storage system was chosen to be installed in Paiyun Lodge on Mt.Jade (Yushan) (the highest lodge in Taiwan).
Models of ideal materials have shown that this zone of plasticity is centered at the crack tip. This equation gives the approximate ideal radius of the plastic zone deformation beyond the crack tip, which is useful to many structural scientists because it gives a good estimate of how the material behaves when subjected to stress. In the above equation, the parameters of the stress intensity factor and indicator of material toughness,
A 2021 review found that people with FM had suicide ideation OR 9.12, suicide attempt OR 3.12, suicide risk OR 36.77 and suicide events HR 1.38, but commented that FM impact could not be separated from the effects of comorbidities and sleep deprivation. A 2020 review found that FM was associated with significantly higher risks for suicidal ideations, suicide attempts and death by suicide compared to the general population. A meta-analysis found that FM people were at a standardized mortality ratio of 1.95 (95% CI 0.97 to 3.92) due to accidents, and 1.66 (95% CI 1.15 to 2.38) due to infections. SMR due to cancer was a decreased rate of 0.82 (95% CI 0.69 to 0.97), perhaps because greater interaction with the health systems of people with FM leads to earlier cancer detection. The studies showed significant heterogeneity. A 2020 review found that many of the core clinical symptoms of FM were more strongly associated with suicidal ideation than with suicidal behaviours.
Other common symptoms which come on rapidly include neuromuscular symptoms, shock, loss of consciousness, hypotension, pallor, ataxia, excessive salivation (oral secretions may become profuse and thick), limb paralysis, nausea and vomiting, ptosis, fever, and severe abdominal pain. Local tissue damage appears to be relatively infrequent and of minor severity in most cases of black mamba envenomation. Edema is typically minimal. Acute kidney injury has been reported in a few cases of black mamba bites in humans as well as in animal models. Death is due to suffocation resulting from paralysis of the respiratory muscles. Untreated black mamba bites have a mortality rate of 100%. Antivenom therapy is the mainstay of treatment for black mamba envenomation. A polyvalent antivenom produced by the South African Institute for Medical Research (SAIMR) is used to treat all black mamba bites from different localities. Because of the availability of antivenom, a bite from a black mamba no longer results in certain death, but in order for the antivenom therapy to be successful, vigorous treatment and large doses of antivenom must be administered rapidly post-envenomation. In case studies of black mamba envenomation, respiratory paralysis has occurred in less than 15 minutes. Envenomation by this species invariably causes severe neurotoxicity because black mambas often strike repeatedly in a single lunge. The doses of antivenom required are often massive (10–30+ vials) for bites from this species.
Duffy announced later that year that work would begin in 2027 and would cost $7 billion, and in May 2026 Amtrak selected out of three finalists a joint venture of Skanska and Halmar International as developer and Vishaan Chakrabarti's Practice for Architecture and Urbanism (PAU) as lead design architect. The approved plan would keep Madison Square Garden in place and rebuild the passenger facilities beneath it. In June 2026, Amtrak and Penn Transformation Partners released renderings for an approximately $8 billion redesign of Penn Station that would retain Madison Square Garden while creating a larger, light-filled station inspired by the original Pennsylvania Station. Later that month, a pre-development agreement (PDA) was finalized, with the project estimated to break ground by the end of 2027. Amtrak also offered to re-add the MTA as a partner in the station's reconstruction, but the MTA declined.
Sources: en.wikipedia.org
Dehydration at 315 °C: 2 NaHSO4 → Na2S2O7 + H2O Cracking at 460 °C: Na2S2O7 → Na2SO4 + SO3 The latter occurs at lower temperatures (around 300 °C) in the presence of catalytic H2SO4. KHSO4 undergoes the same reactions at a higher temperature. Another two step method involving a salt pyrolysis starts with concentrated sulfuric acid and anhydrous tin tetrachloride:
Also, this tail movement can increase the number interactions between the histone tail and the DNA, increasing likelihood of nucleosome formation and potentially leading to the creation of higher-order chromatin structure. In trans, P38 leads to the opposite effects: allowing for Set2 to methylate K36. Set2 is only affected by isomerization of P38 when creating a trimethylated K36 (commonly written as K36me3), however, and not K36me2. Fpr4 also binds to P32 in H4, though its effects are minimal. In mammalian cells, the isomerization of H3P30 interacts with the phosphorylation of H3S28 (serine in the 28 position of histone H3) and the methylation of H3K27. hFKBP25 is a PPIase that is a homolog for Fpr4 in mammalian cells and is found to commonly be associated with the presence of HDACs. Cyp33 is a cyclophilin that has the ability to isomerize H3 proline residues at P16 and P30 positions. Histones H2A and H2B also have multiple proline residues near amino acids that when modified affect the activity surrounding the histone.
PRC military strategists view the first island chain as part of a cordon sanitaire by the US and its allies, intended to encircle the country and limit its strategic depth and maritime security. The first island chain is often cited as a natural barrier and perceived constraint to the PRC's access to the Pacific Ocean. Within the first island chain, the PRC's access to the South China Sea is viewed as crucial for its navy, as the Yellow Sea and East China Sea are considered too shallow for clandestine submarine operations. Control over Taiwan and its deeper eastern waters would provide the People's Liberation Army Navy's ballistic missile submarines with less detectable access to the wider Pacific where they would serve as an important component of a credible second strike capability for the PRC. According to a 2018 United States Department of Defense report to Congress, the People's Liberation Army's Anti-Access/Area Denial military capabilities aimed at the first island chain are its most robust. The report also stated that the People's Liberation Army Navy's ability to perform missions beyond the first island chain is "modest but growing as it gains experience operating in distant waters and acquires larger and more advanced platforms."
Bobby's Vegas Gamble – Covers the opening of Mesa Grill Las Vegas. Restaurant Revamp – Flay tries to help a family restaurant. Chefography: Bobby Flay – Biography of Flay's life and career. Tasting Ireland – Flay takes a food tour of Ireland, his ancestral homeland. Food Network Awards – The Food Network recognizes people and places that have impacted the food world. All-Star Grill Fest: South Beach – Flay joins Paula Deen, Giada De Laurentiis, Alton Brown, and Tyler Florence for a barbecue. In October 2021, Variety reported that Flay would leave Food Network after a 27-year run, after he and the network failed to reach an agreement on a new contract. People reported that Flay had sought $100 million as part of the proposal. In November 2021, it was reported that Flay had signed a new three-year deal with Food Network.
Sources: en.wikipedia.org
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.
It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.
The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.